Phathom Pharmaceuticals reported a sharp rise in Q2 2026 revenue, with year-over-year growth accelerating on stronger product demand. The update also points to

Phathom Pharmaceuticals reported a sharp rise in Q2 2026 revenue, with year-over-year growth accelerating on stronger product demand. The update also points to portfolio expansion, EoE trial progress and a broader U.S. medical affairs buildout.